

August 9, 2011  
AnGes MG, Inc.

**Medical-Use Patent for Ets-1 Granted in the U.S.  
- Intended for Angiogenesis/Gene Therapy Using Transcription Factor, Ets-1 -**

AnGes MG, Inc. is pleased to announce that the medical-use patent for Ets-1 transcription factor intended for angiogenesis/gene therapy was granted in the U.S. and the Patent Gazette (US Patent No. 7,994,151) was issued today.

This patented invention provides a novel gene therapy, in which administration of Ets-1 transcription factor induces angiogenesis, for critical leg ischemia (peripheral occlusive arterial disease), myocardial infarction and angina pectoris.

It has been shown that Ets-1 transcription factor is located upstream of angiogenesis cascade by HGF and VEGF and that it induces angiogenesis through the mediation of HGF and VEGF expressions.

Thus, therapeutic angiogenesis is induced by administration of Ets-1 gene alone. However, by combining with HGF or VEGF, it strengthens the angiogenesis actions of HGF or VEGF and consequently, even better efficacy is expected.

AnGes MG is currently preparing for a global phase 3 clinical trial on HGF gene therapy for peripheral occlusive arterial disease. This patented invention will support future HGF gene therapy development projects aiming for further efficacy after obtaining the approval of HGF gene therapy for peripheral occlusive arterial disease based on the global phase 3 trial.

AnGes MG has filed patent applications in countries, other than the U.S. and is establishing a patent network for its international clinical development.

Japanese Patent Application published: No. 2002-000258

European Patent Application published: No. EP1889633

Korean Patent: No. 10-0798566 (registered in January, 2008)

The above mentioned patents and patent applications, including U.S. patent are valid until June, 2021.

In addition to the current patent, a succession of other HGF gene therapy related medical-use patent applications have been filed in order to expand the scope of clinical applications.

Meanwhile, this trend will have no effect on AnGes MG's business performance for the current fiscal year.